MEG3 noncoding RNA: a tumor suppressor
- PMID: 22393162
- PMCID: PMC3738193
- DOI: 10.1530/JME-12-0008
MEG3 noncoding RNA: a tumor suppressor
Abstract
Maternally expressed gene 3 (MEG3) is an imprinted gene belonging to the imprinted DLK1-MEG3 locus located at chromosome 14q32.3 in humans. Its mouse ortholog, Meg3, also known as gene trap locus 2 (Gtl2), is located at distal chromosome 12. The MEG3 gene encodes a long noncoding RNA (lncRNA) and is expressed in many normal tissues. MEG3 gene expression is lost in an expanding list of primary human tumors and tumor cell lines. Multiple mechanisms contribute to the loss of MEG3 expression in tumors, including gene deletion, promoter hypermethylation, and hypermethylation of the intergenic differentially methylated region. Re-expression of MEG3 inhibits tumor cell proliferation in culture and colony formation in soft agar. This growth inhibition is partly the result of apoptosis induced by MEG3. MEG3 induces accumulation of p53 (TP53) protein, stimulates transcription from a p53-dependent promoter, and selectively regulates p53 target gene expression. Maternal deletion of the Meg3 gene in mice results in skeletal muscle defects and perinatal death. Inactivation of Meg3 leads to a significant increase in expression of angiogenesis-promoting genes and microvessel formation in the brain. These lines of evidence strongly suggest that MEG3 functions as a novel lncRNA tumor suppressor.
Figures




Similar articles
-
Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression.Cancer Res. 2010 Mar 15;70(6):2350-8. doi: 10.1158/0008-5472.CAN-09-3885. Epub 2010 Feb 23. Cancer Res. 2010. PMID: 20179190 Free PMC article.
-
Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas.J Clin Endocrinol Metab. 2008 Oct;93(10):4119-25. doi: 10.1210/jc.2007-2633. Epub 2008 Jul 15. J Clin Endocrinol Metab. 2008. PMID: 18628527 Free PMC article.
-
Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions.Endocrinology. 2010 Mar;151(3):939-47. doi: 10.1210/en.2009-0657. Epub 2009 Dec 23. Endocrinology. 2010. PMID: 20032057 Free PMC article.
-
Maternally expressed gene 3 (MEG3): A tumor suppressor long non coding RNA.Biomed Pharmacother. 2019 Oct;118:109129. doi: 10.1016/j.biopha.2019.109129. Epub 2019 Jul 18. Biomed Pharmacother. 2019. PMID: 31326791 Review.
-
Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach.Mol Cell Endocrinol. 2010 Sep 15;326(1-2):40-7. doi: 10.1016/j.mce.2010.02.040. Epub 2010 Mar 6. Mol Cell Endocrinol. 2010. PMID: 20211686 Free PMC article. Review.
Cited by
-
Harnessing the TP53INP1/TP53I3 axis for inhibition of colorectal cancer cell proliferation through MEG3 and Linc-ROR Co-expression.Heliyon. 2024 Jul 10;10(14):e34075. doi: 10.1016/j.heliyon.2024.e34075. eCollection 2024 Jul 30. Heliyon. 2024. PMID: 39108882 Free PMC article.
-
Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors.Mol Endocrinol. 2015 Feb;29(2):224-37. doi: 10.1210/me.2014-1304. Epub 2015 Jan 7. Mol Endocrinol. 2015. PMID: 25565142 Free PMC article.
-
LncRNA MEG3 Participates in Caerulein-Induced Inflammatory Injury in Human Pancreatic Cells via Regulating miR-195-5p/FGFR2 Axis and Inactivating NF-κB Pathway.Inflammation. 2021 Feb;44(1):160-173. doi: 10.1007/s10753-020-01318-6. Inflammation. 2021. PMID: 32856219
-
Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia.Oncotarget. 2016 Dec 13;7(50):82400-82410. doi: 10.18632/oncotarget.12252. Oncotarget. 2016. PMID: 27689399 Free PMC article.
-
LncRNA MEG3 inhibits rheumatoid arthritis through miR-141 and inactivation of AKT/mTOR signalling pathway.J Cell Mol Med. 2019 Oct;23(10):7116-7120. doi: 10.1111/jcmm.14591. Epub 2019 Aug 14. J Cell Mol Med. 2019. PMID: 31411001 Free PMC article.
References
-
- Astuti D, Latif F, Wagner K, Gentle D, Cooper WN, Catchpoole D, Grundy R, Ferguson-Smith AC, Maher ER. Epigenetic alteration at the DLK1–GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms’ tumour. British Journal of Cancer. 2005;92:1574–1580. (doi:10.1038/sj.bjc.6602478) - PMC - PubMed
-
- Bando T, Kato Y, Ihara Y, Yamagishi F, Tsukada K, Isobe M. Loss of heterozygosity of 14q32 in colorectal carcinoma. Cancer Genetics and Cytogenetics. 1999;111:161–165. (doi:10.1016/S0165-4608(98)00242-8) - PubMed
-
- Biller BM, Alexander JM, Zervas NT, Hedley-Whyte ET, Arnold A, Klibanski A. Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing's disease. Journal of Clinical Endocrinology and Metabolism. 1992;75:1303–1309. (doi:10.1210/jc.75.5.1303) - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous